败血症
医学
全身炎症反应综合征
临床意义
外科
胃肠病学
内科学
作者
Hisatake Matsumoto,Kazuma Yamakawa,Hiroshi Ogura,Taichin Koh,Naoya Matsumoto,Takeshi Shimazu
出处
期刊:Shock
[Lippincott Williams & Wilkins]
日期:2016-10-06
卷期号:47 (4): 409-415
被引量:22
标识
DOI:10.1097/shk.0000000000000768
摘要
Activated immune cells such as monocytes are key factors in systemic inflammatory response syndrome (SIRS) following trauma and sepsis. Activated monocytes induce almost all tissue factor (TF) expression contributing to inflammation and coagulation. TF and CD13 double-positive microparticles (TF+/CD13+MPs) are predominantly released from these activated monocytes. This study aimed to evaluate TF+/CD13+MPs and assess their usefulness as a biomarker of pathogenesis in early SIRS following trauma and sepsis. This prospective study comprising 24 trauma patients, 25 severe sepsis patients, and 23 healthy controls was conducted from November 2012 to February 2015. Blood samples were collected from patients within 24 h after injury and diagnosis of severe sepsis and from healthy controls. Numbers of TF+/CD13+MPs were measured by flow cytometry immediately thereafter. Injury Severity Score (ISS) and Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores were calculated at patient enrollment. APACHE II and SOFA scores and International Society of Thrombosis and Haemostasis (ISTH) overt disseminated intravascular coagulation (DIC) diagnostic criteria algorithm were calculated at the time of enrollment of severe sepsis patients. Numbers of TF+/CD13+MPs were significantly increased in both trauma and severe sepsis patients versus controls and correlated significantly with ISS and APACHE II score in trauma patients and with APACHE II and ISTH DIC scores in severe sepsis patients. Increased numbers of TF+/CD13+MPs correlated significantly with severities in the acute phase in trauma and severe sepsis patients, suggesting that TF+/CD13+MPs are important in the pathogenesis of early SIRS following trauma and sepsis.
科研通智能强力驱动
Strongly Powered by AbleSci AI